ライフサイエンスコーパス: ESRD

1 ESRD and non-ESRD patients receiving antibiotics was 520

2 ESRD is considered a central outcome, and a method for e

3 ESRD patients also had a similar rate of major vascular

4 ESRD patients had a higher in-hospital mortality (5.1% v

5 ESRD patients were younger, male, and African American.

6 ESRD was determined as the need for chronic dialysis or

7 patients with AF and ESRD on OAC with 3,018 ESRD patients without OAC.

8 The prescription incidence was 1359.95/1000 ESRD vs 673.61/1000 non-ESRD patients.

9 ansplant knowledge items to a sample of 1294 ESRD patients.

10 Overall, 176 (0.50%) and 429 (1.21%) ESRD events occurred within 2 and 5 years, respectively.

11 sectional, single-center study comprising 32 ESRD patients and 38 controls.

12 48,100 infections were treated in 35,369 ESRD patients and 2,544,443 infections treated in 3,777,

13 median follow-up of 5 years, we observed 70 ESRD events and 48 deaths.

14 A total of 8107 ESRD-HD patients with aortic stenosis were included, 413

15 year (C-statistic 0.924, 95% 0.909 to 0.938) ESRD prediction.

16 We telephone surveyed 528 adult ESRD patients of black or white race referred for evalua

17 ncentration, and CKD stage at onset affected ESRD risk.

18 Year 5 in NHBs and Year 4 in Hispanics after ESRD onset.

19 panics (versus NHWs) in the first year after ESRD, but by Year 4, access to transplantation was not s

20 With an aging ESRD population and continued organ shortage, preservati

21 We compared the outcomes among ESRD-HD Medicare beneficiaries who were managed with TAV

22 m(2), incident CKD, eGFR decline >/=30%, and ESRD over a median follow-up of 8.52 years.

23 per 1.73 m(2), CKD, eGFR decline >/=30%, and ESRD.

24 >/=30% (HR, 1.28; 95% CI, 1.18 to 1.39), and ESRD (HR, 1.26; 95% CI, 1.17 to 1.35).

25 res used to match 1,519 patients with AF and ESRD on OAC with 3,018 ESRD patients without OAC.

26 utilization was low in patients with AF and ESRD.

27 e cohort included 8,410 patients with AF and ESRD.

28 Patients with CKD and ESRD have increased in-hospital mortality and periproced

29 , but their association with risk of CKD and ESRD is unknown.

30 Diabetes is the main cause of CKD and ESRD worldwide.

31 y disease, a condition that leads to CKD and ESRD.

32 4-2011; main outcome measures were death and ESRD.

33 and risk of incident CKD, eGFR decline, and ESRD.

34 y similarities between postdonation ESRD and ESRD in the general population, about which much is alre

35 The consistent associations between HCM and ESRD were shown in almost all subgroups other than smoke

36 dditional patients with multiple myeloma and ESRD and, more recently, to tolerance induction strategi

37 anging projections of population obesity and ESRD death rates.

38 ny other tissues, with systemic oxalosis and ESRD being a common outcome.

39 bution, obesity and diabetes prevalence, and ESRD survival will result in a 11%-18% increase in the c

40 ociation between these hemoglobin traits and ESRD remains unknown.

41 e changes and acceptable end points, such as ESRD, has limited its utility.

42 cantly between patients with IgAN-associated ESRD and patients with ESRD from other causes.

43 ted nephropathy, and hypertension-attributed ESRD among people of recent African ancestry.

44 seldom develop baseline hyponatremia before ESRD.

45 t common primary glomerular disorder causing ESRD, is a complex disease that is only partially unders

46 e timing of dialysis initiation in a Chinese ESRD population than eGFR, and may be a helpful tool to

47 tudy, but ongoing trials also center on CKD, ESRD, and AKI.

48 CKD or ESRD with those patients with no CKD/ESRD.

49 ing one such pilot project-the Comprehensive ESRD Care (CEC) initiative-to include patients with adva

50 a composite of doubling of serum creatinine, ESRD, or death between 100 Rtx-treated patients and 103

51 famethoxazole dosage was elevated by current ESRD guidelines.

52 eferral eligibility in those who did develop ESRD, and referred the latter at a younger age and with

53 ls eligible for referral who did not develop ESRD, increased the likelihood of referral eligibility i

54 from living donors who subsequently develop ESRD also have higher graft failure, suggesting the two

55 or nkSOT recipients who subsequently develop ESRD derive survival benefit from KT, but graft longevit

56 lier referrals in those who go on to develop ESRD.

57 ion is to treat nkSOT recipients who develop ESRD with a kidney transplant (KT), an increasing number

58 of 15 (26%) positive patients had developed ESRD or died.

59 w-up of 6.9 years, 844 individuals developed ESRD, and 853 died.

60 nt (KT), an increasing number are developing ESRD at an older age where KT may not be the most approp

61 1 tended to have a higher risk of developing ESRD (HR, 3.60 95% CI 1.83-7.07) compared with nonchroni

62 ociated with an increased risk of developing ESRD and suggests that elevated serum levels of HCV RNA

63 ubsequently develop end-stage renal disease (ESRD) also have higher graft failure, suggesting the 2 d

64 r of posttransplant end-stage renal disease (ESRD) and mortality.

65 Patients with end-stage renal disease (ESRD) are characterized by increased cardiovascular (CV)

66 es in patients with end-stage renal disease (ESRD) compared to healthy controls.

67 Patients with end-stage renal disease (ESRD) due to lupus nephritis (LN) have high rates of pre

68 ver (FMF) who reach end-stage renal disease (ESRD) due to reactive amyloidosis A (AA) are scarce and

69 m 1,5-AG levels and end-stage renal disease (ESRD) from baseline (1990-1992) through 2013 with adjust

70 lowly progresses to end-stage renal disease (ESRD) in about half of these individuals.

71 ey disease (CKD) or end stage renal disease (ESRD) is generally caused due to the progressive loss of

72 ted immigrants with end-stage renal disease (ESRD) live in the United States.

73 23, 1.15-1.33), and end-stage renal disease (ESRD) or >=50% decline in eGFR (1.17, 1.05-1.30).

74 al factors preclude end-stage renal disease (ESRD) patients from initiating kidney transplant evaluat

75 treatment for most end-stage renal disease (ESRD) patients, but proportionally few ESRD patients rec

76 (HCV) infection and end-stage renal disease (ESRD) remains controversial without considering the role

77 t generate lifetime end-stage renal disease (ESRD) risks for young living kidney donors have conflict

78 mellitus (DM), and end-stage renal disease (ESRD) were calculated by Poisson regression stratified b

79 Participants with end-stage renal disease (ESRD) were excluded.

80 nt complications of end-stage renal disease (ESRD) with few studies having investigated oral antibiot

81 pecially those with end-stage renal disease (ESRD), are controversial.

82 predict the risk of end stage renal disease (ESRD), i.e., the need for dialysis or a kidney transplan

83 patients developed end-stage renal disease (ESRD), major cardiovascular event (mCVE), and de novo ca

84 In patients with end-stage renal disease (ESRD), surgical aortic valve replacement is associated w

85 1%-18% will develop end stage renal disease (ESRD).

86 ultiple myeloma and end-stage renal disease (ESRD).

87 with development of end-stage renal disease (ESRD).

88 k of progression to end-stage renal disease (ESRD).

89 on in patients with end-stage renal disease (ESRD).

90 ISA) in adults with end-stage renal disease (ESRD).

91 ion between HCM and end-stage renal disease (ESRD).

92 re in the same way as eventual post-donation ESRD.

93 ypertension is a frequent event before donor ESRD; thus, early postdonation hypertension might indica

94 Given that donor ESRD is rare, an earlier and more common post-donation o

95 Given that donor ESRD is rare, an earlier and more common postdonation ou

96 ertension is a frequent event prior to donor ESRD; thus early post-donation hypertension might indica

97 e of adjudicated death due to renal failure, ESRD, or sustained 40% or higher decrease in eGFR from b

98 ease (ESRD) patients, but proportionally few ESRD patients receive kidney transplant.

99 Aggressive pain treatment was advocated for ESRD patients, but new Centers for Disease Control and P

100 isease etiology, improve risk assessment for ESRD, and pave the way for personalized treatment.

101 peritoneal dialysis patients in the CRC for ESRD prospective cohort from 2008 to 2014 were enrolled

102 king pre-ESRD death as a competing event for ESRD.

103 We assessed risk factors for ESRD using multivariate Cox regression models.

104 3 m, the adjusted subdistribution hazard for ESRD was 1.41 (confidence interval [CI], 1.2-1.5), 2.15

105 mate subdistribution hazard ratios (HRs) for ESRD.

106 as well as to age-sex matched mortality for ESRD-HD in the US population.

107 Planning for ESRD resource allocation should allow for substantial co

108 ojections can inform long-range planning for ESRD resources needs.

109 HCM was a significant predictor for ESRD (unadjusted HR 6.90, 95% CI 5.21-9.15, p < 0.001),

110 The incidence rate for ESRD among participants with APOL1 high-risk genotypes w

111 In the HCM, the incidence rate for ESRD gradually increased with age, but an initial peak a

112 The incidence rate for ESRD was 8.5 per 1000 person-years for participants with

113 er quartiles combined had a hazard ratio for ESRD of 1.24 (95% confidence interval [95% CI], 1.05 to

114 r 1000 person-years, with a hazard ratio for ESRD of 1.77 (95% confidence interval, 1.31 to 2.38) for

115 individuals with SCT had a hazard ratio for ESRD of 2.03 (95% confidence interval, 1.44 to 2.84).

116 specific symptoms, skin, and respiratory for ESRD; and respiratory, nonspecific symptoms, and genitou

117 d mesangial expansion and decreased risk for ESRD (subdistribution HR, 0.64; 95% confidence interval,

118 ESRD in blacks, and this degree of risk for ESRD was similar to that conferred by APOL1 high-risk ge

119 r bone marrow and kidney transplantation for ESRD due to multiple myeloma.

120 ocial Security Death Index; 397 patients had ESRD and 475 deaths occurred during a median follow-up o

121 erapies) registry, 3,053 (4.2%) patients had ESRD and were compared with patients who were not on dia

122 ith end-stage renal disease on hemodialysis (ESRD-HD) and aortic stenosis have poor prognosis.

123 ictor of all-cause mortality in hemodialyzed ESRD patients.

124 food frequency questionnaire and identified ESRD via record linkage with a nationwide registry.

125 In ESRD-HD patients with aortic stenosis, mortality was low

126 erior sector of the RNFL scan (p = 0.021) in ESRD patients were still significantly thinner.

127 In conclusion, chronic exposure to FO in ESRD is a strong risk factor for death across discrete B

128 gic stroke, and bleeding hospitalizations in ESRD patients treated with or without OAC.

129 trajectory does not explain any increase in ESRD after donation.

130 The increase in ESRD incidence rates within age and race groups has leve

131 L, p = 0.042) of the right eye were lower in ESRD patients.

132 ion project, the Time to Reduce Mortality in ESRD (TiME) trial, evaluating effects of session duratio

133 The impact of oral anticoagulation (OAC) in ESRD patients is uncertain.

134 a novel intervention to improve olfaction in ESRD.

135 stigates antibiotic prescribing practices in ESRD across New York State (NYS).

136 his incidence trend along with reductions in ESRD mortality will increase the number of patients with

137 he increased morbidity and mortality seen in ESRD patients receiving emergency-only hemodialysis.

138 ridioides difficile (CDI) infections seen in ESRD.

139 c tool to optimize CV risk stratification in ESRD and other high-risk CV cohorts.

140 study was to describe patterns of OAC use in ESRD patients with AF and their associations with cardio

141 Incident ESRD occurred in 40 of 739 (5.4%) individuals with SCT,

142 ssive decline in renal function and incident ESRD in patients with ADPKD, and may aid early identific

143 We investigated incident ESRD during follow-up in 10,300 adult patients with HCM

144 a 3.38-fold increase in the risk of incident ESRD.

145 suPAR levels and follow-up eGFR or incident ESRD.

146 sus men) and outcomes, specifically incident ESRD (defined as undergoing dialysis or a kidney transpl

147 Primary outcomes were incident ESRD, eGFR slope, log-transformed UPCR slope, and all-ca

148 h mortality in 39,566 patients with incident ESRD in a large dialysis network in 26 countries using w

149 leep fragmentation associated with increased ESRD risk (hazard ratio, 1.04; 95% confidence interval,

150 Evidence suggests that for HIV-infected ESRD patients, KT is associated with a significant survi

151 ty-affiliated hemodialysis centers involving ESRD patients with poor attendance, defined as missing 2

152 gn to young adults about 70% of the lifetime ESRD that they will experience as they age, which is par

153 (LN)-associated end-stage renal disease (LN-ESRD) in African Americans.

154 Patients with incident LN-ESRD who were waitlisted for a renal transplant.

155 ring the study period, 9659 patients with LN-ESRD were waitlisted for a renal transplant, of whom 573

156 with up to one in four patients manifesting ESRD within 20 years of diagnosis.

157 ive management compared with age-sex matched ESRD-HD US population were 1.24, 1.27, and 1.83, respect

158 To reliably and validly measure ESRD patients' kidney transplant knowledge, rigorously t

159 nce was 1359.95/1000 ESRD vs 673.61/1000 non-ESRD patients.

160 ,544,443 infections treated in 3,777,314 non-ESRD patients.

161 study from 2016 to 2017 of NYS ESRD and non-ESRD patients analyzing Medicare part B billing codes, 7

162 ESRD and non-ESRD patients receiving antibiotics was 520.29/1000 and

163 nspecific symptoms, and genitourinary in non-ESRD.

164 But the nonspecific ESRD risk factors identified in this study are likely fe

165 case-control study from 2016 to 2017 of NYS ESRD and non-ESRD patients analyzing Medicare part B bil

166 CAKUT causes approximately 40% of ESRD that manifests within the first three decades of li

167 The burden of ESRD will increase in the United States population throu

168 IgAN was associated with one extra case of ESRD per 54 person-years.

169 F/TAF averted 2101 fractures and 25 cases of ESRD for the 123 610 MSM receiving PrEP, with an ICER of

170 In all, 951 cases of ESRD occurred over a mean follow-up of 15.5 years.

171 ney diseases (ADPKD), a significant cause of ESRD, and autosomal dominant polycystic liver diseases (

172 , and more likely to have GN as the cause of ESRD.

173 Diabetes is the leading cause of ESRD.

174 In the United States, incidence of ESRD is 1.5 times higher in men than in women, despite m

175 urces of protein may reduce the incidence of ESRD.

176 ne the kidney transplant knowledge levels of ESRD patients and plan appropriate interventions to ensu

177 trict BP control does not delay the onset of ESRD but may reduce the relative risk of death in CKD.

178 externally validate the KFRE's prediction of ESRD events in primary care, perform model recalibration

179 s, HCM itself remained a robust predictor of ESRD development (adjusted HR 3.93, 95% CI 2.82-5.46, p

180 and HCV genotype 1 are strong predictors of ESRD, indicating clinical implications for the managemen

181 on renal biopsy as independent predictors of ESRD.

182 to estimate the incidence and prevalence of ESRD in the United States through 2030 on the basis of w

183 simulation models to develop projections of ESRD incidence and prevalence.

184 The incidence rates of ESRD for nonchronically HCV-infected and chronically HCV

185 blacks continue to have much higher rates of ESRD than HIV-positive whites, which could be attributed

186 Pre-DM increases the risk of ESRD and mCVE; however, patient survival was comparable

187 BP lowering and its association with risk of ESRD are unclear.

188 brated KFRE accurately predicted the risk of ESRD at 2 and 5 years in primary care.

189 tion processes has identified higher risk of ESRD attributable to donation in two studies; importantl

190 Predicted 20-year risk of ESRD for the median donor was only 34 cases per 10,000 d

191 An increased risk of ESRD has been reported for living kidney donors, and app

192 usual BP arm associated with higher risk of ESRD in AASK (aHR, 1.83; 95% CI, 1.30 to 2.57) and MDRD

193 eGFR decline associated with higher risk of ESRD in both strict and usual BP arms.

194 nd a method for estimating long-term risk of ESRD in donor candidates is described.

195 ring did not associate with a higher risk of ESRD in the AASK (adjusted hazard ratio [aHR], 1.19; 95%

196 hat red meat intake may increase the risk of ESRD in the general population and substituting alternat

197 od sources of dietary protein on the risk of ESRD in the general population remain unclear.

198 Our findings show that risk of ESRD post-heart transplant increases with worsening eGFR

199 Patients who are at risk of ESRD should be identified before transplantation.

200 d high HCV RNA levels were at higher risk of ESRD than those who were nonchronically HCV-infected (HR

201 the AASK trials, unadjusted relative risk of ESRD was 0.88 (95% CI, 0.78 to 1.00) and unadjusted rela

202 Despite the highest risk of ESRD with the lowest baseline eGFR group, there was a su

203 h men, women had significantly lower risk of ESRD, 50% eGFR decline, progression to CKD stage 5, and

204 Conclusively, HCM increased the risk of ESRD, regardless of known prognosticators.

205 trials in CKD associated with higher risk of ESRD, we performed a retrospective study of 899 African

206 airy products did not associate with risk of ESRD.

207 The risks of ESRD and mCVE were significantly higher in patients with

208 of >/=50% decrease in eGFR from baseline or ESRD, occurred in 15 intensive group and 16 standard gro

209 Patients with CKD or ESRD had greater in-hospital mortality, hospital length

210 in-hospital outcomes of patients with CKD or ESRD with those patients with no CKD/ESRD.

211 rait did not associate with prevalent CKD or ESRD.

212 Compared with the nondialysis patients, ESRD patients were younger (76 years vs. 83 years; p < 0

213 ggest many similarities between postdonation ESRD and ESRD in the general population, about which muc

214 ure in the same way as eventual postdonation ESRD.

215 e estimated the average risk of postdonation ESRD for living kidney donors in the United States, but

216 at the time of waitlisting on posttransplant ESRD and mortality.

217 association remained robust after taking pre-ESRD death as a competing event for ESRD.

218 Mortality preceding ESRD was not significantly increased compared with contr

219 trend in deaths due to the growing prevalent ESRD population, we calculated quarterly relative mortal

220 ed the proportion of patients with prevalent ESRD in each facility referred for transplant within 1 y

221 d Centers for Medicare and Medicaid Services ESRD death data from 2000 to 2013.

222 o [IRR] range, 4.84-13.4 across age strata), ESRD (IRR range, 3.30-9.02), CAD (IRR range, 2.77-10.7),

223 One possibility is that ESRD is due to the nephrectomy-related reduction in GFR,

224 The ESRD Prospective Payment System associated with a 5.0% (

225 The ESRD Prospective Payment System bundling, but not the tr

226 The ESRD Prospective Payment System introduced two incentive

227 The ESRD Quality Incentive Program (QIP) is the first mandat

228 We evaluated the effects of the ESRD Prospective Payment System on home dialysis use by

229 ssment and quality measures, focusing on the ESRD QIP, its effect on care, and its potential future d

230 The QIP is tied to the ESRD prospective payment system and mandated by the Medi

231 dress the transition of patients from CKD to ESRD, a particularly vulnerable time for patients.

232 or prognostic indicators of time from DKD to ESRD.

233 iable option for many who have progressed to ESRD.

234 that, in most patients, slowly progresses to ESRD.

235 diabetic kidney disease (DKD) progression to ESRD are lacking.

236 ongly associated with risk of progression to ESRD in blacks, and this degree of risk for ESRD was sim

237 int of 30% decline in eGFR or progression to ESRD over a median of 1.8 and 2.0 years of follow up, re

238 ong the highest risks for CKD progression to ESRD.

239 ue of histologic findings in DKD for time to ESRD in native kidney specimens from biopsies performed

240 for association with proteinuria and time to ESRD.

241 tistically significant in predicting time to ESRD.

242 The primary outcome was ESRD or 50% reduction in eGFR.

243 ll cause mortality and secondary outcome was ESRD.

244 idney transplant recipients (1996-2011) with ESRD attributed to one of six GN subtypes or two compara

245 decline in eGFR, and 17.0% (13.1-20.4%) with ESRD or >=50% decline in eGFR.

246 alysis at a higher eGFR level in adults with ESRD does not improve survival.

247 nal study was conducted with 176 adults with ESRD on regular hemodialysis.

248 This SNP also associated with ESRD (hazard ratio, 2.0 (95% confidence interval, 1.5 to

249 were no longer significantly associated with ESRD (IRR = 0.92, 95% CI: 0.81, 1.05).

250 is known regarding outcomes associated with ESRD opioid prescription.

251 Red meat intake strongly associated with ESRD risk in a dose-dependent manner (hazard ratio for h

252 Overall, 8% of 754,777 beneficiaries with ESRD underwent at least one lower extremity amputation i

253 ow-back study of Medicare beneficiaries with ESRD who died in 2002 through 2014 to analyze patterns o

254 ial disparities in survival of children with ESRD is not clear.

255 In children with ESRD, a higher eGFR at dialysis initiation is associated

256 gnosis for four out of nine individuals with ESRD of unknown etiology.

257 similar treatment for multiple myeloma with ESRD.

258 rocurement and Transplantation Network, with ESRD ascertainment via Centers for Medicare and Medicaid

259 participants with CKD, 100 participants with ESRD, and 25 controls.

260 Patients with ESRD (n = 1281) who commenced haemodialysis from 2008 to

261 ntion strategies are needed in patients with ESRD and AF.

262 nt and outcomes in a cohort of patients with ESRD and AF.

263 in is protective or harmful in patients with ESRD and atrial fibrillation.

264 tes, with approximately 50% of patients with ESRD attributed to diabetes in developed countries.

265 tion (RRF) confers survival in patients with ESRD but declines after initiating hemodialysis.

266 ty will increase the number of patients with ESRD by 29%-68% during the same period to between 971,00

267 Patients with ESRD exhibited higher odor threshold than the remaining

268 with IgAN-associated ESRD and patients with ESRD from other causes.

269 s, contributes to mortality in patients with ESRD has not been quantified.

270 Background Patients with ESRD have a substantially increased cancer risk, but few

271 eart failure, and mortality in patients with ESRD on maintenance hemodialysis.

272 Adjusted analyses of patients with ESRD showed that those who had undergone lower extremity

273 Patients with ESRD suffer an exceptionally high cardiovascular risk no

274 Nearly one in ten patients with ESRD undergoes lower extremity amputation in their last

275 ajor source of morbidity among patients with ESRD undergoing maintenance hemodialysis and is a signif

276 Older patients with ESRD who receive a kidney transplant (KT) may develop po

277 care needs among seriously ill patients with ESRD who undergo amputation as well as opportunities to

278 n about end-of-life care among patients with ESRD who undergo amputation.

279 ity amputation is common among patients with ESRD, and often portends a poor prognosis.

280 tion in all-cause mortality in patients with ESRD, with ILI likely contributing to >1000 deaths annua

281 all-cause and CV mortality in patients with ESRD.

282 and end-of-life care among the patients with ESRD.

283 ed growth in the population of patients with ESRD.

284 ges in Medicare can affect all patients with ESRD.

285 ore in five out of seven (71%) patients with ESRD.

286 neurodegenerative processes in patients with ESRD.

287 ermine the outcomes of TAVR in patients with ESRD.

288 vulnerable populations such as patients with ESRD.

289 thout (n = 757) a first-degree relative with ESRD.

290 Patients undergoing TAVR with ESRD are at higher risk and had higher in-hospital morta

291 10, 95% CI 0.70-1.73, p=0.68) and those with ESRD caused by hypertension (aHR 1.10, 95% CI 0.65-1.85,

292 , 95% CI 0.70-1.73, P = 0.68) and those with ESRD caused by hypertension (aHR 1.10, 95% CI 0.65-1.85,

293 Outcomes of veterans with ESRD may differ depending on where they receive dialysis

294 red with 1% of 958,412 beneficiaries without ESRD.

295 h a parallel cohort of beneficiaries without ESRD.

296 period analysis of 528,108 patients without ESRD before admission, from October of 2012 to September

297 ; importantly, however, the absolute 15-year ESRD incidence in donors remains very low (0.3%).

298 l criteria based on a KFRE-calculated 5-year ESRD risk of >=5% and/or an ACR of >=70 mg/mmol reduced

299 Ten-year ESRD-free survival rates were 43%, 94%, and 72% in child

300 During follow-up (median 2.8 years), ESRD developed in 197 subjects; 111 (1.08%) in the HCM,